Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy: The POSEIDON Randomized Trial
Mesenchymal stem cells (MSCs) are under evaluation as a therapy for ischemic cardiomyopathy (ICM). Both autologous and allogeneic MSC therapies are possible; however, their safety and efficacy have not been compared. The objective of the POSEIDON Randomized Trial was to test whether allogeneic MSCs are as safe and effective as autologous MSCs in patients with left ventricular (LV) dysfunction due to ICM. In this early-stage study of patients, transendocardial injection of allogeneic and autologous MSCs without a placebo control were both associated with low rates of treatment-emergent SAEs, including immunologic reactions. In aggregate, MSC injection favorably affected patient functional capacity, quality of life, and ventricular remodeling. read more »
Cardiac cell therapy trials using adult bone marrow cells (BMC) were the subject of a large meta-analysis that showed that transplantation in patients with ischemic heart disease offers lasting improvements in key cardiac metrics compared with conventional therapy alone. read more »
In a field characterized by mixed results and variable protocols, a large meta-analysis shows that transplantation of adult bone marrow cells (BMC) in patients with ischemic heart disease offers lasting improvements in key cardiac metrics compared with standard therapy alone. The study also suggests that the experimental treatment improves clinical outcomes.
In March 2012, Leslie W. Miller, MD, FACC led discussions for CME credits with Deepak L. Bhatt, MD, MPH; Timothy Henry, MD; Emerson C. Perin, MD, PhD on The Promise of Adipose-Derived Regenerative Cells in Cardiovascular Medicine.
Dr. Miller holds the Edward C. Wright Chair of Cardiovascular Medicine at University of South Florida (USF) and is the Director/ CEO of the USF Cardiovascular Clinical and Research Integrated Strategic Program, or CRISP. In addition, Dr. Miller is a member of the Okyanos Medical Advisory Council. Each of these leaders in cardiology provided insights and understandings as well as areas that need further exploration in the field of cardiac cell therapy. read more »